A Case Report on Brucellosis

Authors
Dr Sumi Marium Saj1, Dr Gopinatha Menon2*, Dr Rukhsar3
1Registrar, Department of Internal Medicine, KIMS HEALTH, Trivandrum, Kerala, India
2Senior Coordinator- Department of Internal Medicine, KIMS HEALTH Trivandrum Kerala, India
3IMT Resident- Department of Internal Medicine, KIMSHEALTH Trivandrum Kerala, India
*Corresponding Author
Dr Gopinatha Menon

Abstract
Brucellosis is a zoonotic disease which is showing a rising trend. This should be an integral differential in every clinician’s minds when presented with a case of pyrexia of unknown origin. We report a case of brucellosis with no complications, to reiterate the need for prevention rather than cure and identifying high risk cases demonstrating therapeutic failure. Treatment therapies and duration vary amongst pregnant and individuals with complications however monotherapy regimens are not accepted. Emphasis on patient education and prevention would be the best approach for disease control. Screening contacts of an index case and offering post exposure prophylaxis should be incorporated in to the physician’s treatment plan.

Keywords: Zoonotic, Brucellosis, antibiotic resistance, monotherapy, screening.

Introduction
Brucellosis is a zoonotic infection caused by gram negative coccobacilli transmitted to humans from infected animals. Four brucella species, B. melitensis (isolated mainly from sheep and goats), B. abortus (isolated from cattle), B. suis (isolated from swine), and B. canis (isolated from dogs) cause human diseases.

Epidemiology
Worldwide, approximately 500,000 cases are reported annually[1], and it is increasing due to the boom in international tourism[2,3]. About 80% of people live within close contact to domestic livestock in the Indian subcontinent however the true incidence of human brucellosis is still unknown. Seroprevalence studies in India suggest infection may range between 0.9% – 18.1%. [4] and long-term serological studies indicate baseline seroprevalence of 5% in cattle and 3% in buffalo[5].

Transmission
Common mechanisms for transmission of brucellosis to humans are[1,2] consumption of infected, unpasteurized animal products such as raw milk, soft cheese, butter, ice cream, raw or undercooked meat, contact of skin/mucous membranes with infected animal tissue (placenta or miscarriage products) or infected animal fluids (blood, urine, milk) and inhalation of infected aerosolized particles.

Brucellosis is an occupational disease in shepherds, veterinarians, dairy-industry professionals and lab personnel. Human-to-human transmission from
blood transfusion, tissue transplantation, breastfeeding, congenital transmission, and sexual transmission have also rarely been described.\(^6\) Brucellae taken up by lymphocytes, enter regional lymph nodes, and seed throughout the reticuloendothelial system. The incubation period ranges from two to four weeks.\(^1,10\) Chronic brucellosis refers to persisting clinical manifestations more than one year after the diagnosis of brucellosis is established.\(^10,11\)

**Laboratory Findings**

Elevated transaminases, anemia, leukopenia /leukocytosis and thrombocytopenia.\(^1,12,13,14\) In Brucella arthritis, synovial fluid white blood cell count is usually ≤15,000 cells/microL (lymphocyte-predominant).\(^15-18\) The organism can be cultured in synovial fluid.\(^19,20\)

Neuro- brucellosis, cerebrospinal fluid shows pleocytosis (10-200 wbc, predominantly mononuclear cells), elevated protein levels, ADA and hypoglycorrachia.\(^21,22\) Organism may be cultured rarely in CSF or antibody/agglutination tests may be used to establish the diagnosis.\(^22\)

In Genitourinary involvement, pyuria can be observed and organism can be cultured.\(^23,24\)

Following treatment, rates of relapse is 5 to 15 percent.\(^25\) Relapse occurs within the first six to twelve months following completion of treatment usually due to inappropriate antibiotic regimen, inadequate duration of therapy, poor compliance, or localized foci of infection.\(^28\) Relapse due to antibiotic resistance is quite rare.

**Case Report**

A 57-yearold dairy farmer hailing from Kerala, diabetic on oral hypoglycaemic agents, presented with history of fever for the past one month. Fever was intermittent in nature and associated with night sweats. He denied complaints of cough/cold/joint pain or any other localizing symptoms. Patient also complained of weight loss, 10kgs over the past six months.

Examination revealed normal vitals and mild splenomegaly on abdomen examination.

A presumptive diagnosis of Brucellosis was made and patient was initiated on Inj Gentamicin 5mg/kg OD and C.Doxycycline 100mg BD for 10 days followed by C.Doxycycline 100mg BD + Rifampin 600mg OD for 6 weeks. Definitive diagnosis requires a positive culture or at least a fourfold rise in Brucella antibody titre obtained more than two weeks apart.\(^29,30\)

| Hb/TC/Platelets       | 14.9/4800/1.22 |
|-----------------------|----------------|
| SGOT/SGPT             | 106/105        |
| Creatinine            | 0.8            |
| Urine culture         | No growth      |
| Blood culture         | No growth      |
| Sputum c/s            | Normal commensals |
| Sputum gene expert    | Negative       |
| Peripheral smear      | No malarial parasites. No blast cells |

- **Lepto, Scrub, Dengue and Salmonella IgM** Negative

- **Brucella antibodies IgM (Serum EIA)** 1.60 (Positive >1.1)
- **Brucella antibodies IgG (Serum EIA)** 0.54 (Negative <0.9)
- **Serum brucella agglutination** 1/1280 (Positive>1/160)
- **USG abdomen** Mild splenomegaly
- **2D echo** Normal valves, no vegetations
- **ECG/Chest X-ray** Normal study

**Discussion**

Relapse, complications and therapeutic failure rates are high and thus deem the necessity for prevention. Measures must be undertaken to boil or pasteurize dairy products, and cook meat thoroughly. Standard infection control precautions such as protective attire and disinfection must be upheld when in contact with infected fluids or tissue. Unprotected sexual contact and breast feeding prior to completion of treatment must be discouraged.\(^31\) There are no available vaccines for humans however live attenuated vaccines for domestic livestock is and efforts should be taken to incorporate it in to ranchers’ yearly vaccination schedules.
Household members of an index case should be screened and ideally offered repeat titers after 12 weeks.[33] Personnel with high risk exposure should be offered post exposure prophylaxis.[34,35] Periodic follow up and patient education on compliance, symptoms of relapse and sequelae is crucial. Brucellosis continues to be underreported yet a common zoonoses and as prevention is better than cure, strides must be taken in identifying a targeted audience and educating them.

**Acknowledgement**

Dr Rajalakshmi, Department of Infectious Diseases, KIMS Health TVM, Micro labs India-Coimbatore

**References**

1. Bosilkovski M, Dimzova M, Grozdanovski K. Natural history of brucellosis in an endemic region in different time periods. Acta Clin Croat 2009.
2. Greenfield RA, Drevets DA, Machado LJ, et al. Bacterial pathogens as biological weapons and agents of bioterrorism. Am J Med Sci 2002.
3. Pappas G, Panagopoulou P, Christou L, Akritidis N. Brucella as a biological weapon. Cell Mol Life Sci 2006.
4. Agasthya AS, Isloor S, Prabhudas K. Brucellosis in high risk group individuals. Indian J Med Microbiol. 2007 Jan.
5. Mantur BG, Amarnath SK. Brucellosis in India – a review. J Biosci. 2008
6. Poulou A, Markou F, Xipolitos I, Skandalakis PN. A rare case of Brucella melitensis infection in an obstetrician during the delivery of a transplacentally infected infant. J Infect 2006.
7. Mesner O, Riesenber K, Biliar N, et al. The many faces of human-to-human transmission of brucellosis: congenital infection and outbreak of nosocomial disease related to an unrecognized clinical case. Clin Infect Dis 2007.
8. Mantur BG, Mangalgi SS, Mulimani M. Brucella melitensis--a sexually transmissible agent? Lancet 1996.
9. Wang W, Liao Q, Wu X, et al. Potential risk of blood transfusion-transmitted brucellosis in an endemic area of China. Transfusion 2015.
10. Mantur BG, Amarnath SK, Shinde RS. Review of clinical and laboratory features of human brucellosis. Indian J Med Microbiol 2007.
11. SPINK WW. What is chronic brucellosis? Ann Intern Med 1951.
12. Bosilkovski M, Krteva L, Dimzova M, et al. Human brucellosis in Macedonia - 10 years of clinical experience in endemic region. Croat Med J 2010.
13. Doganay M, Aygen B. Human brucellosis: An overview. Int J Infect Dis 2003.
14. Karakucku M, Patiroglu T, Ozdemir MA, et al. Pancytopenia, a rare hematologic manifestation of brucellosis in children. J Pediatr Hematol Oncol 2004.
15. Sommers H M. The microbiology laboratory in the diagnosis of infectious arthritis. Clin Rheum Dis 1978.
16. Goldenberg DL, Reed JI. Bacterial arthritis. N Engl J Med 1985.
17. Julkunen H. Reactive arthritis. Bull Rheum Dis 1979.
18. Andonopoulos AP, Asimakopoulos G, Anastasiou E, Bassaris HP. Brucella arthritis. Scand J Rheumatol 1986.
19. Al-Eissa YA, Kambal AM, Alrabeelah AA, et al. Osteoarticular brucellosis in children. Ann Rheum Dis 1990.
20. Gotuzzo E, Alarcón GS, Bocanegra TS, et al. Articular involvement in human brucellosis: a retrospective analysis of 304 cases. Semin Arthritis Rheum 1982.
21. Erdem H, Kilic S, Sener B, et al. Diagnosis of chronic brucellar meningitis and meningoencephalitis: the results of the Istanbul-2 study. Clin Microbiol Infect 2013.
22. Guven T, Ugurlu K, Ergonul O, et al. Neurobrucellosis: clinical and diagnostic features. Clin Infect Dis 2013.
23. Conkar S, Kosker M, Cevik S, Ay M. Association of brucellosis with renal tubular and glomerular damage in children in Turkey. Saudi J Kidney Dis Transpl 2018.
24. Demiroğlu YZ, Turunç T, Alişkan H, et al. [Brucellosis: retrospective evaluation of the clinical, laboratory and epidemiological features of 151 cases].
25. Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med 2007.
26. Ariza J, Corredoira J, Pallares R, et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis 1995.
27. Roushan MR, Gangi SM, Ahmadi SA. Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis. Swiss Med Wkly 2004.
28. Solera J, Martínez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997.
29. Al Dahouk S, Tomaso H, Nöckler K, et al. Laboratory-based diagnosis of brucellosis--a review of the literature. Part II: serological tests for brucellosis. Clin Lab 2003.
30. Mantecón Mde L, Gutiérrez MP, Zarzosa Mdel P, et al. Influence of brucellosis history on serological diagnosis and evolution of patients with acute brucellosis. J Infect 2008.
31. Solera J, Martínez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997.
32. WHO Brucellosis in humans and animals Geneva: World Health Organization, 2006.
33. Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med 2007.
34. Julkunen H. Reactive arthritis. Bull Rheum Dis 1979.
35. Andonopoulos AP, Asimakopoulos G, Anastasiou E, Bassaris HP. Brucella arthritis. Scand J Rheumatol 1986.